September 9, 2008 - Lantheus Medical Imaging Inc. issued a statement assuring regulatory authorities, key customers and partners that they will continue to receive supply of molybdenum-99 (Mo-99), the parent isotope of Technetium-99m (Tc-99m) in their TechneLite generators, during the current global isotope shortage and will continue to fulfill preexisting standing orders and try to meet additional demands during this critical time.
Lantheus said it will continue to serve the needs of patients and the nuclear medicine community, and to mitigating the effect this shortage has on nuclear imaging studies and patient care.
On several past occurrences of Tc-99m generator supply issues, Lantheus faced similar challenges and was able to address supply demands. Lantheus said it is fully prepared for this current situation and has requested additional production of Mo-99 to ensure the company is once again well-positioned in the face of increased customer demand.
The company will continue to supply the medical isotope to the worldwide markets until complete resolution of these shortage issues.
For more information: www.radiopharm.com
July 30, 2024 
